MarketPulse

Complete Response Letter

22 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Corcept Therapeutics Faces Class Action Over Relacorilant Clinical Evidence Claims

Corcept Therapeutics faces class action lawsuit for allegedly misleading statements about relacorilant's clinical evidence. FDA rejected the drug application, causing stock to plummet 50%.
CORTclass action lawsuitstock decline
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Geller Rudman & Dowd Llp

Corcept Therapeutics Faces Class Action Over Relacorilant FDA Rejection

Corcept Therapeutics faces class action lawsuit over alleged misrepresentation regarding relacorilant drug. FDA rejected the application citing insufficient efficacy data; stock plummeted over 50%.
CORTsecurities fraudclass action lawsuit